Airborne Contact Dermatitis in 1,203 of 201,344 Patch-Test Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: How often was airborne dermatitis diagnosed in a 201,344-patient patch-test network?
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 201,344 consecutively patch-tested IVDK patients, including 1,203 diagnosed with airborne contact dermatitis and 421 with an occupational background. |
| Design | Retrospective clinical-surveillance analysis of demographic, occupational and patch-test data. |
| Comparator | The 1,203 airborne cases were compared with 200,141 patients without airborne contact dermatitis; occupational and nonoccupational cases were also contrasted. |
| Timepoint | 1994-2013. |
| Key result | Airborne contact dermatitis was diagnosed in 0.6% of the patch-tested cohort; 421 of 1,203 cases had an occupational background. Epoxy resin and MCI/MI sensitization were significantly associated with the airborne diagnosis. |
| Funding/conflict context | The indexed abstract does not state funding or conflicts and did not test Dr. Arsy #003. |
What was actually measured?
Airborne contact dermatitis was diagnosed in 0.6% of the patch-tested cohort; 421 of 1,203 cases had an occupational background. Epoxy resin and MCI/MI sensitization were significantly associated with the airborne diagnosis.
The denominator is a patch-tested clinical population, so 0.6% is not general-population or workforce prevalence.
The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.
What the result does not prove
Referral selection, retrospective diagnostic classification, changing allergens and practices over 20 years and exposure documentation quality limit inference.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.
Exposure detail matters more than the job label
Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve on days away or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredient information and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 26234324
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Objective Skin-Barrier Measures in 185 Physicians, Dentists and Controls
- Hand-to-Forearm Barrier Measures in 148 Physicians and Dentists
- Workplace-Irritant Assessment in 316 Suspected Hand-Dermatitis Patients
- Aniline-Epoxy Allergy in Nine Helicopter-Assembly Workers
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.